Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Palo Alto Investors LP

Key Points

• Palo Alto Investors LP has reduced its position in Alnylam Pharmaceuticals by 40.7%, owning 83,488 shares after selling 57,193 shares during the first quarter.
• Alnylam Pharmaceuticals reported $0.32 EPS for the last quarter, exceeding estimates by $0.86 and achieving revenue of $773.69 million, up 17.3% year-over-year.
• Several analysts have upgraded their price targets for Alnylam Pharmaceuticals, with Piper Sandler increasing theirs from $304 to $449 and maintaining an "overweight" rating.

Palo Alto Investors LP lessened its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 40.7% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 83,488 shares of the biopharmaceutical company's stock after selling 57,193 shares during the period. Alnylam Pharmaceuticals accounts for about 4.3% of Palo Alto Investors LP's portfolio, making the stock its 7th largest position. Palo Alto Investors LP owned 0.06% of Alnylam Pharmaceuticals worth $22,543,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the business. Investment Management Corp of Ontario boosted its holdings in Alnylam Pharmaceuticals by 0.6% during the fourth quarter. Investment Management Corp of Ontario now owns 7,099 shares of the biopharmaceutical company's stock worth $1,670,000 after buying an additional 40 shares during the last quarter. Brevan Howard Capital Management LP raised its position in shares of Alnylam Pharmaceuticals by 3.4% during the fourth quarter. Brevan Howard Capital Management LP now owns 1,333 shares of the biopharmaceutical company's stock worth $314,000 after purchasing an additional 44 shares during the period. Northwestern Mutual Wealth Management Co. raised its position in shares of Alnylam Pharmaceuticals by 10.3% during the first quarter. Northwestern Mutual Wealth Management Co. now owns 525 shares of the biopharmaceutical company's stock worth $142,000 after purchasing an additional 49 shares during the period. Lindbrook Capital LLC raised its position in shares of Alnylam Pharmaceuticals by 9.2% during the first quarter. Lindbrook Capital LLC now owns 596 shares of the biopharmaceutical company's stock worth $161,000 after purchasing an additional 50 shares during the period. Finally, SYM FINANCIAL Corp raised its position in shares of Alnylam Pharmaceuticals by 5.3% during the first quarter. SYM FINANCIAL Corp now owns 1,014 shares of the biopharmaceutical company's stock worth $274,000 after purchasing an additional 51 shares during the period. Institutional investors own 92.97% of the company's stock.

Wall Street Analysts Forecast Growth

ALNY has been the topic of a number of research analyst reports. Wolfe Research raised Alnylam Pharmaceuticals from an "underperform" rating to a "peer perform" rating in a research report on Monday, August 4th. Scotiabank raised their price target on shares of Alnylam Pharmaceuticals from $342.00 to $450.00 and gave the stock a "sector outperform" rating in a research note on Friday, August 1st. Morgan Stanley lifted their target price on Alnylam Pharmaceuticals from $312.00 to $405.00 and gave the company an "equal weight" rating in a research report on Friday, August 1st. Wall Street Zen cut Alnylam Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Friday. Finally, JPMorgan Chase & Co. upped their price objective on Alnylam Pharmaceuticals from $348.00 to $475.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 6th. Twenty-two analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, Alnylam Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average target price of $417.38.

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ ALNY traded down $1.54 during midday trading on Friday, hitting $452.00. 751,495 shares of the company's stock were exchanged, compared to its average volume of 1,065,318. The company has a quick ratio of 2.75, a current ratio of 2.80 and a debt-to-equity ratio of 4.10. Alnylam Pharmaceuticals, Inc. has a 12 month low of $205.87 and a 12 month high of $469.81. The company's 50 day moving average price is $387.47 and its 200 day moving average price is $309.71. The firm has a market capitalization of $59.25 billion, a PE ratio of -183.00 and a beta of 0.32.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 EPS for the quarter, topping the consensus estimate of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The company had revenue of $773.69 million during the quarter, compared to the consensus estimate of $633.54 million. During the same period in the previous year, the company posted ($0.13) EPS. The firm's revenue for the quarter was up 17.3% compared to the same quarter last year. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, CEO Yvonne Greenstreet sold 6,979 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $453.27, for a total transaction of $3,163,371.33. Following the completion of the sale, the chief executive officer directly owned 56,221 shares of the company's stock, valued at approximately $25,483,292.67. This trade represents a 11.04% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Jeffrey V. Poulton sold 2,274 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $453.27, for a total value of $1,030,735.98. Following the sale, the executive vice president directly owned 50,121 shares of the company's stock, valued at approximately $22,718,345.67. The trade was a 4.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 57,594 shares of company stock worth $25,551,456 in the last 90 days. Company insiders own 1.50% of the company's stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.